Other defined subtypes are characterised by human epidermal growth factor receptor 2 (HER2) protein overexpression or HER2 gene amplification, and triple negative breast cancer (TNBC), where there is neither ER/PR expression nor HER2 overexpression2,3. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.